LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | NVP-TAE684 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 3310 | 3643 | 0.9095 | 0.8604 |
| SK-BR-3 | NVP-TAE684 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 2530 | 3643 | 0.6942 | 0.5092 |
| SK-BR-3 | NVP-TAE684 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1545 | 3643 | 0.4247 | 0.0348 |
| SK-BR-3 | NVP-TAE684 | 10 | uM | LJP6 | 72 | hr | 1476 | 965 | 3643 | 0.2650 | -0.2800 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 4222 | 3772 | 1.1193 | 1.1735 |
| SK-BR-3 | CGP60474 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 922 | 3643 | 0.2527 | -0.3062 |
| SK-BR-3 | CGP60474 | 0.12 | uM | LJP5 | 72 | hr | 1476 | 2041 | 3772 | 0.5411 | 0.2701 |
| SK-BR-3 | CGP60474 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 918 | 3643 | 0.2531 | -0.3064 |
| SK-BR-3 | CGP60474 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 1380 | 3772 | 0.3659 | -0.0495 |
| SK-BR-3 | CGP60474 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 999 | 3643 | 0.2748 | -0.2599 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 1172 | 3772 | 0.3108 | -0.1583 |
| SK-BR-3 | CGP60474 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 992 | 3643 | 0.2723 | -0.2649 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1041 | 3772 | 0.2760 | -0.2278 |
| SK-BR-3 | CGP60474 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 852 | 3643 | 0.2335 | -0.3474 |
| SK-BR-3 | CGP60474 | 10 | uM | LJP5 | 72 | hr | 1476 | 846 | 3772 | 0.2244 | -0.3387 |
| SK-BR-3 | CGP60474 | 10 | uM | LJP6 | 72 | hr | 1476 | 732 | 3643 | 0.2016 | -0.4177 |
| SK-BR-3 | PD173074 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 4309 | 3643 | 1.1824 | 1.2748 |
| SK-BR-3 | PD173074 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 4293 | 3643 | 1.1784 | 1.2700 |
| SK-BR-3 | PD173074 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 4062 | 3643 | 1.1173 | 1.1824 |
| SK-BR-3 | PD173074 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 4269 | 3643 | 1.1728 | 1.2634 |
| SK-BR-3 | PD173074 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 4220 | 3643 | 1.1605 | 1.2471 |
| SK-BR-3 | PD173074 | 10 | uM | LJP6 | 72 | hr | 1476 | 1980 | 3643 | 0.5443 | 0.2529 |
| SK-BR-3 | Crizotinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2870 | 3772 | 0.7610 | 0.6344 |
| SK-BR-3 | Crizotinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3203 | 3772 | 0.8495 | 0.7729 |
| SK-BR-3 | Crizotinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 2825 | 3772 | 0.7490 | 0.6149 |